EP4188389
DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASE
:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á Íslandi:
1.4.2021:
17.9.2025:
21716724.6
:
31.3.2041:
31.3.2026
:
DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASE
1.4.2021
17.9.2025
31.3.2026
:
AstraZeneca AB:
151 85 Södertälje, SE
:
LANGKILDE, Anna Maria:
151 85 Södertälje, SE
:
202063057139 P:
27.7.2020:
US
:
202063070869 P:
27.8.2020:
US
:
202063082524 P:
24.9.2020:
US
:
202063093961 P:
20.10.2020:
US
:
202063119711 P:
1.12.2020:
US
:
202163152445 P:
23.2.2021:
US
:
202163161629 P:
16.3.2021:
US
:
EP2021058727:
1.4.2021
:
A61K 31/70, A61P 31/12